Organon & Co.
General ticker "OGN" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $2.3B (TTM average)
Organon & Co. follows the US Stock Market performance with the rate: 21.2%.
Estimated limits based on current volatility of 0.7%: low 13.22$, high 13.41$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-05-11, amount 0.02$ (Y0.60%)
- Total employees count: 10000 (0.0%) as of 2024
- China accounted for 13.2% of revenue in the fiscal year ended 2024-12-31
- US accounted for 10.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Geopolitical risks, Market competition, Acquisition/divestiture risks, Regulatory and compliance
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.95$, 12.79$]
- 2026-12-31 to 2027-12-31 estimated range: [8.20$, 16.24$]
Financial Metrics affecting the OGN estimates:
- Positive: with PPE of 1.9 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 38.31 > 12.90
- Positive: Operating profit margin, % of 20.67 > 18.39
- Positive: Industry inventory ratio change (median), % of 0.28 <= 0.28
- Positive: Industry operating profit margin (median), % of 24.71 > 9.60
- Negative: Interest expense per share per price, % of 27.58 > 3.31
- Negative: Shareholder equity ratio, % of 5.84 <= 19.24
- Positive: Industry earnings per price (median), % of 5.49 > 4.45
Short-term OGN quotes
Long-term OGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6,263.00MM | $6,403.00MM | $6,216.00MM |
| Operating Expenses | $4,936.00MM | $4,917.00MM | $4,931.00MM |
| Operating Income | $1,327.00MM | $1,486.00MM | $1,285.00MM |
| Non-Operating Income | $-654.00MM | $-679.00MM | $-860.00MM |
| Interest Expense | $527.00MM | $520.00MM | $504.00MM |
| R&D Expense | $528.00MM | $469.00MM | $366.00MM |
| Income(Loss) | $673.00MM | $807.00MM | $425.00MM |
| Taxes | $-350.00MM | $-57.00MM | $238.00MM |
| Net Income(Loss)* | $1,023.00MM | $864.00MM | $187.00MM |
| Stockholders Equity | $-70.00MM | $472.00MM | $752.00MM |
| Inventory | $1,315.00MM | $1,321.00MM | $0.00MM |
| Assets | $12,058.00MM | $13,101.00MM | $12,867.00MM |
| Operating Cash Flow | $799.00MM | $939.00MM | $700.00MM |
| Capital expenditure | $261.00MM | $351.00MM | $162.00MM |
| Investing Cash Flow | $-260.00MM | $-513.00MM | $-390.00MM |
| Financing Cash Flow | $-569.00MM | $-368.00MM | $-561.00MM |
| Earnings Per Share** | $4.01 | $3.36 | $0.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.